Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Transplant Proc ; 42(5): 1643-7, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20620492

ABSTRACT

BACKGROUND AND PURPOSE: The influence of African-American ethnicity on outcomes of kidney transplant recipients subjected to early steroid withdrawal remains controversial. Recent studies that suggest no higher risk among African Americans may be biased by recruitment of relatively small number of African Americans or by patient selection. We compared outcomes of African Americans to non-African Americans in a center in which early steroid withdrawal has become the standard of practice. METHODS: This was a single-center prospective study of 133 consecutive patients receiving primary kidney transplants between January 2006 and December 2008, followed for >or=3 months, and managed with a similar immunosuppression regimen that included induction antibody therapy, tacrolimus, mycophenolate mofetil, and withdrawal of steroids on postoperative day 5. Acute rejection and other outcomes were compared in African-American patients (n = 55) and compared with those of non-African-American patients (n = 78). RESULTS: During the first 12 months after early steroid withdrawal, African-American patients experienced a significantly higher cumulative incidence of acute rejection than non-African Americans (23.6% vs 7.7%; P = .020). Using multivariate logistic regression, ethnicity (odds ratio 3.33; P = .047) and HLA mismatch (odds ratio 1.44; P = .041) were significantly correlated with acute rejection independent of recipient age, gender, historical peak panel reactive antibody level (PRA) or PRA at time of transplant, time on dialysis, or donor source. CONCLUSIONS: African Americans are at increased risk of acute rejection after early steroid withdrawal, particularly when they receive kidneys from poorly matched donors.


Subject(s)
Adrenal Cortex Hormones/therapeutic use , Black or African American/statistics & numerical data , Ethnicity/statistics & numerical data , Graft Rejection/epidemiology , Kidney Transplantation/physiology , Adult , Aged , Drug Administration Schedule , Drug Therapy, Combination , HLA Antigens/immunology , Histocompatibility Testing , Humans , Immunosuppressive Agents/therapeutic use , Kidney Transplantation/immunology , Living Donors/statistics & numerical data , Methylprednisolone/administration & dosage , Methylprednisolone/therapeutic use , Middle Aged , Prednisone/administration & dosage , Prednisone/therapeutic use , Substance Withdrawal Syndrome/epidemiology
2.
Am J Transplant ; 10(2): 310-4, 2010 Feb.
Article in English | MEDLINE | ID: mdl-20055793

ABSTRACT

Proteinuria is an increasingly recognized effect of sirolimus (SRL) therapy in kidney transplant recipients. Predictors of proteinuria after conversion to SRL are not well described, and in particular the risk in African-American (AA) kidney recipients is unknown. We sought to analyze risk factors for proteinuria with SRL therapy in a cohort of 39 patients (44% AA) converted from tacrolimus to SRL at a mean time of 4 months posttransplantation. Patients were maintained on therapy with mycophenolate mofetil while most patients underwent early steroid withdrawal. Urinary protein to creatinine ratio (Up/cr) at a mean of 14 months postconversion increased to > or =500 mg/g in 65% of AAs versus 14% of non-AAs (p = 0.001). Mean arterial blood pressure at the time of conversion and pretransplant proteinuric kidney disease were also predictors of proteinuria after SRL conversion. In conclusion, AAs appear to be at high risk for proteinuria and should be monitored closely after conversion to SRL in calcineurin inhibitor sparing protocols.


Subject(s)
Immunosuppressive Agents/therapeutic use , Kidney Diseases/physiopathology , Kidney/physiopathology , Proteinuria/chemically induced , Adult , Female , Humans , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/pharmacology , Kidney Diseases/chemically induced , Kidney Diseases/drug therapy , Kidney Function Tests , Male , Middle Aged , Mycophenolic Acid/analogs & derivatives , Proteinuria/drug therapy , Proteinuria/physiopathology , Risk Factors , Sirolimus/adverse effects , Sirolimus/pharmacology , Sirolimus/therapeutic use , Steroids/pharmacology , Steroids/therapeutic use , Tacrolimus/pharmacology , Tacrolimus/therapeutic use
3.
Am J Kidney Dis ; 23(4): 605-18, 1994 Apr.
Article in English | MEDLINE | ID: mdl-8154501

ABSTRACT

The inherited diseases of the glomerular basement membrane include Alport's syndrome (AS), nail-patella syndrome, and thin basement membrane nephropathy. Classical AS is inherited in an X-linked manner and accounts for approximately 85% of the cases. Its manifestations include hematuria, sensorineural hearing loss, ocular defects, and a progression to renal failure. A defect(s) in the alpha 5 (IV) chain of type IV collagen is believed to be the etiology of classic AS, and alterations in its encoding gene localized to the X-chromosome have been elucidated. Although isolated cases of anti-glomerular basement membrane glomerulonephritis have been reported following renal transplantation in patients with AS, it is considered an effective form of renal replacement therapy. Less is known regarding the genetic basis of the autosomal-dominant form of AS, which apparently accounts for the remaining 15% of the cases. Nail-patella syndrome is characterized by nail dysplasia, patellar hypoplasia or aplasia, and nephropathy. It is inherited in an autosomal-dominant fashion with the gene locus assigned to the long arm of chromosome 9. Possible linkage between the COL5A1 gene and the gene for nail-patella syndrome has been suggested. Approximately 30% of the patients progress to end-stage renal failure. Renal transplantation has been successful in treating patients who progress to end-stage renal failure. Thin basement membrane nephropathy is an autosomal dominant trait that accounts for approximately 30% of the cases presenting as persistent, asymptomatic hematuria. The cause of thin basement membrane nephropathy is unknown at present. No decline in renal function is associated with thin basement membrane nephropathy.


Subject(s)
Collagen Type IV , Kidney Glomerulus/pathology , Nephritis, Hereditary/pathology , Adolescent , Adult , Autoantigens/immunology , Basement Membrane/immunology , Basement Membrane/pathology , Basement Membrane/ultrastructure , Collagen/immunology , Female , Humans , Kidney Glomerulus/immunology , Kidney Glomerulus/ultrastructure , Male , Nail-Patella Syndrome/genetics , Nail-Patella Syndrome/pathology , Nephritis, Hereditary/genetics , Nephritis, Hereditary/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...